• HIV DART 2022: Speaker Evaluation and Needs Assessment

    Thank you for attending the HIV DART 2022. Please take a few minutes to complete our after-session survey as it will help us improve future HIV DART meetings and offer relevant content to our attendees.
  • About you: Please select your professional role (single choice)*

  • Have you been to a DART conference before?*
  • What is your area of expertise*

  • Are you an industry professional?*

  • Session 1: HIV latency, reservoirs and advances in cure strategies

    Sunday, Dec 4, 2022, 15:45-17:25
  • Plenary lecture: HIV infection in the COVID era: Monica Gandhi, University of California San Francisco, USA
    Rows
  • HIV Cure: Latency & reservoirs: Basic science and pre-clinical developments: Mathias Lichterfeld , Harvard University, USA
    Rows
  • When Does The HIV-1 Reservoir Form?: Sarah Joseph, University of North Carolina at Chapel Hill, USA
    Rows
  • SUMOylation by the SMC5/6 complex epigenetically silences unintegrated HIV-1 DNA leading to post-integration viral latency: Bryan Cullen, Duke University, USA
    Rows

  • Session 2: Gertrude Elion Distinguished Lecturer Award session

    Monday, Dec 5, 2022, 8:30-9:10
  • Gertrude Elion Distingushed Lecturer Award Lecture: “A tale of three scrounges”: Recipient: James W. Curran, Emory University, USA
    Rows

  • Session 3: Cutting edge developments in prevention and HIV therapeutics

    Monday, Dec 5, 2022, 9:10-10:30
  • Plenary Lecture: Implementation and clinical management of injectable antiretrovirals for treatment: Michael Saag, University of Alabama Birmingham, USA
    Rows
  • Impact of subtype on antiretroviral drugs for treatment and prevention: Rami Kantor, Brown University, USA
    Rows
  • CCR5 in HIV prevention and cure:Jonah Sacha, Oregon Health & Science University, USA
    Rows

  • Session 4: Industry Session: Long acting formulations (non-CME session)

    Monday, Dec 5, 2022, 11:00-11:55
  • ViiV Long acting Formulations program: Justin Koteff, ViiV Healthcare, USA
    Rows
  • Merck Long acting Formulations program: Rafael Campo, Merck, USA
    Rows
  • Gilead Long acting Formulations program: Martin Rhee, Gilead, USA
    Rows

  • Oral Abstract: Session 1

    Monday, Dec 5, 2022, 11:55-12:35
  • The pDC/IFN-I inflammatory pathway in HIV-1 pathogenesis and metabolic dysregulation: Lishan Su, Institute of Human Virology, USA
    Rows
  • Selection of HIV-1 for resistance to fifth generation protease inhibitors reveals two independent pathways to high-level resistance: Ronald Swanstrom, University of North Carolina at Chapel Hill, USA
    Rows
  • GRL142 binds to and impairs HIV-1-Integrase-Nuclear localizing signal and exerts potent activity against INSTI-resistant HIV-1: Manabu Aoki
    Rows
  • The first-in-human clinical trial of STP0404, a novel potent HIV-1 allosteric integrase inhibitor: Xue Meng, ST Pharm Co Ltd, South Korea
    Rows
  • The first-in-human clinical trial of STP0404, a novel potent HIV-1 allosteric integrase inhibitor: Xue Meng, ST Pharm Co Ltd, South Korea
    Rows

  • HIV DART 2022 Poster Session

    Monday, Dec 5, 2022, 15:00-16:30
  • Poster Session
    Rows

  • Session 5: Immunity, Vaccines, Inflammation, NeuroAIDS, & aging

    Monday, Dec 5, 2022, 16:30-17:50
  • Plenary lecture: Inflammation, neuroAIDS, aging and co-morbidities: Serena Spudich, Yale University, USA
    Rows
  • Insights from Host Epigenetic Scars towards addressing HIV Complications: Lishowma Ndhlova, Cornell University, USA
    Rows
  • Keynote Lecture: HIV cure: hopes and bottlenecks: Michaela Müller-Trutwin, Institut Pastuer, France
    Rows

  • Session 6: Conceptual Shifts to mitigate the HIV Crisis

    Tuesday, Dec 6, 2022, 8:30-9:30
  • Plenary Lecture: Role of macrophages in the context of HIV & the brain: Victor Garcia-Martinez, University of North Carolina Chapel Hill, USA
    Rows
  • The HIV epidemic in Latin America: a time to reflect on the history of success and the challenges ahead: Alvaro López Iñiguez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
    Rows
  • On the way to overcoming HIV/AIDS in Eastern Europe: challenges, scenarios and perspectives: Alexey Mazus, National Virus Association, Russia
    Rows

  • Oral Abstract Session 2

    Tuesday, Dec 6, 2022, 9:40-10:30
  • Development of an immunomodulatory AAV viral vector to minimizing adaptive immune responses to AAV-delivered broadly neutralizing antibodies: James Termini, University of Miami, USA
    Rows
  • Identification of HLA-E-binding HIV-1 and HIV-2 Env-derived peptides and cytokine modulation of NKG2A/C+ NK and NKG2A/C+ CD8+ T cells: Aurelio Otra Resendiz, Institut Pasteur, France
    Rows
  • Long-term ART-free SIV remission following allogeneic hematopoietic cell transplantation in mauritian cynomolgus macaques: Helen Wu, Vaccine Gene & Therapy Institute, Oregon Health & Science University USA
    Rows
  • Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever infection: Gabriela Webb, Oregon Health and Science University, USA
    Rows
  • Combating yellow fever virus With 2’-Dihalo-Uridine nucleoside analogs: Julia LeCher, Emory University, USA
    Rows

  • Debate Session

    Do we really need a cure for HIV when we already have ART?
  • The pro perspective - Mario Stevenson & ??
    Rows
  • The con perspective - Steve Deeks & ??
    Rows
  • Based on the arguments that you heard today, do we really need a cure for HIV when we already have ART?

  • Needs Assessment

  • Please rate to which extent you agree with the following statement:
    Rows
  • The following meeting objectives were met during HIV DART 2022:
    Rows
  • What needs/ gaps do you feel currently exist in this field of research?
    Rows
  • Did this year's program address this gap/need?
    Rows

  • Intent to Change

  • Please rate to which extent you agree with the following statements:
    Rows

  • Overall Meeting Experience

  • Please rate to which extent you agree with the following statements:
    Rows

  • Logistics Experience

  • Please rate to which extent you agree with the following statements:
    Rows

  • Your feedback is extremely important to us and will help improve the program for future years. Thank you for Completing the Survey for HIV DART 2022!

     

    Happy Holidays!

    Conference Secretariat

    HIV DART 2022

  • Should be Empty: